University of Washington starts 2nd generation Covid-19 vaccine trial Tammy Mutasa, KOMO News
Replay Video UP NEXT
SEATTLE Even as vaccinations are ramping up stubborn variants are fueling the alarming rise in cases and hospitalizations around the country.
The CDC now says the highly contagious United Kingdom variant is the most dominant coronavirus strain in the United States.
The variants are causing trouble at a time when UW Medicine has started a new trial for a second generation Covid-19 vaccine intended to provide more protection against future Covid variants.
On the cusp of a 4th wave, health experts fear nasty variants are fueling the surge.
Search jobs 02-Feb-2021 LB Pharmaceuticals Announces the Initiation of Patient Dosing in Open Label Phase 1b Imaging Study of LB-102
NEW YORK (BUSINESS WIRE) #LB102 LB Pharmaceuticals Inc, (“LB”) a biotechnology company focused on developing and commercializing novel and improved versions of successful CNS treatments, announced today the administration of the first dose of LB-102 in a Phase 1b clinical trial (Clinical Trials Identifier NCT04588129). This clinical study is designed to evaluate the dopamine receptor occupancy of LB-102 in healthy subjects using positron emission tomography (PET).
LB-102, a more lipophilic version of amisulpride, was designed to improve on amisulpride’s notoriously poor membrane (BBB) permeability while matching amisulpride’s binding affinity to the D